Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on FluoGuide announcing results from the first part of the ongoing CT-005 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer (HNC).</li><li>The focus in Part 1 was on finding the optimal dose, which was achieved.</li><li>While definitive margin assessment data are still under analysis, we view this readout as the best possible outcome at this stage, as meeting the primary dose-finding endpoint with a clean safety profile bodes well for the trial’s progression.</li></ul>

Redeye comments on FluoGuide announcing results from the first part of the ongoing CT-005 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer (HNC).The focus in Part 1 was on finding the optimal dose, which was achieved.While definitive margin assessment data are still under analysis, we view this readout as the best possible outcome at this stage, as meeting the primary dose-finding endpoint with a clean safety profile bodes well for the trial’s progression.

FluoGuide: First part of Phase 2 HNC trial clears dose-finding phase

Fluoguide

FluoGuide: First part of Phase 2 HNC trial clears dose-finding phase